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CHAPTER I 
Celiac Disease 
 
Coeliac disease (CD) is a systemic immune-mediated disorder elicited by gluten in 
genetically susceptible individuals. All patients with CD have a variable combination of 
gluten-dependent clinical manifestations, specific autoantibodies (anti-tissue 
transglutaminase/anti-endomysium), HLA-DQ2 and/or DQ8 haplotypes and different 
degrees of enteropathy, including severe villous atrophy, intraepithelial lymphocytes 
infiltration and crypt hyperplasia. These features are used  to classify CD using the 
Modified Marsh Classification (Oberhuber) (1). 
CD is considered a disease that involves both acquired and innate cell mediated immunity 
(2).  
The gluten peptides, after crossing the epithelium into the lamina propria, are deamidated 
by tissue transglutaminase and then presented by DQ2+ or DQ8+ antigen-presenting cells 
to pathogenic CD4+ T cells (3,4). Once activated, the CD4+ T cells drive a T-helper-cell 
type 1 response that leads to the development of coeliac lesions. Activated gluten-reactive 
CD4+ T-cells produce high levels of pro-inflammatory cytokines, thus inducing a T-
helper-cell–type-(Th)1 pattern dominated by interferon gamma (IFN-γ). Th-1 cytokines 
promote inflammatory effects including fibroblast or lamina propria mononuclear cell 
(LPMC) secretion of matrix metalloproteinases (MMPs), which are responsible for 
degradation of extracellular matrix and basement membrane, and increased cytotoxicity of 
intraepithelial lymphocytes (IELs) or natural killer (NK) T cells. These latter facilitate the 
apoptotic death of enterocytes by the Fas/Fas ligand (FasL) system, or interleukin 15 (IL-
15)(5). IL-15, produced mainly by monocytes/macrophages, dendritic and epithelial cells, 
is a pro-inflammatory cytokine involved both in adaptive and in innate immunity. Memory 
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CD4+ and CD8+ T cells, NKT, NK, and TCRγ/δ+ cells expand following stimulation with 
IL-15 (6). Furthermore, IL-15 is also a potent growth factor for the intraepithelial 
lymphocytes (IEL) (7), whose density is significantly increased in CD, representing its 
hallmark. IL-15 is highly expressed not only in lamina propria cells but also in the 
intestinal epithelium of untreated CD patients and in patients with refractory celiac sprue, a 
premalignant condition, characterized by a massive IEL infiltration in particular of 
abnormal TCRγ/δ+ cells (8). The finding that in CD IL-15 is not secreted but bound to 
enterocyte cellular membrane, strengthened the hypothesis that IL-15 produced by 
epithelial cells, could be the main factor orchestrating the selective expansion of IEL, 
particularly TCRγ/δ+ and CD8 + TCR α/β+ lymphocytes bearing the CD94 NK receptor 
(9,10). It is noteworthy to mention that, in normal condition, intestinal TCRγ/δ+ cells 
recognize stress-inducible, MHC Class I-like molecules MICA and MICB, expressed on 
damaged epithelial cells (11). MICA and MICB proteins interacting with NKG2D receptor 
expressed on TCRγ/δ+ and NK cells, are found to activate innate cytotoxic and cytokine 
production responses. By contrast, the MICA ligation of NKG2D on CD8 + TCR α/β+ 
enhances the adaptive, antigen-specific cell-mediated responses (12). Importantly, a very 
recent study indicate that MICA molecules are strongly expressed on epithelial cells of CD 
patients with acute disease and upregulated both in the epithelium and LP of treated 
following gliadin peptide challenge (13). Also in this case IL-15 seems to play a crucial 
role. These studies pinpoint the fundamental role of innate immune response in the damage 
of intestinal mucosal tissues in CD, primarily due to the cytolysis of epithelial layer 
mediated by MICA/NKG2D activated IEL (13) 
Interferon alfa (IFN-α) released by activated dendritic cells perpetuates the inflammatory 
reaction by inducing CD4+ T cells to produce IFN-γ. Additionally, through the production 
of Th-2 cytokines, activated CD4+ T-cells drive the activation and clonal expansion of B 
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cells, which differentiate into plasma cells and produce antigliadin and anti-tTG 
antibodies(14). By interacting with the extracellular membrane-bound tTG (mtTG), tTG-
autoantibody deposits in the basement-membrane region might induce enterocyte 
cytoskeleton changes with actin redistribution and consequent epithelial damage (5). 
 
 
 
 
   Figure 1. Mechanisms of mucosal damage in coeliac disease 
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1. The role of undigested gluten peptides 
 
The term gluten mainly refers to wheat storage proteins. It is an extremely heterogeneous 
mixture of proteins, which are classified as gliadins and glutenins. Gliadins are monomeric 
proteins that are subdivided into α/β-, γ-, and ω-fractions according to their electrophoretic 
profile. Glutenins are present as polymeric complexes that are comprised of two subunit 
types, the high molecular weight and the low molecular weight subunits (15-16). A 
common feature of gluten proteins is the presence of a high level of proline and glutamine 
residues, which renders gluten highly resistant to proteolytic degradation in the 
gastrointestinal tract.(17,18). Consequently, the released peptides can cross the gut 
epithelial barrier and reach the lamina propria of the intestinal mucosa, triggering two 
immunological pathways: the adaptive and the innate immune responses (19).  
Tissue transglutaminase (TG2), a Ca++ dependent enzyme, catalyzes both in vivo 
(epithelial brush border and subepithelial TG2) and in vitro the de-amidation of specific 
glutamine residues to glutamic acid, and enhances stimulatory capacity of gliadin-derived 
peptides by strengthening the binding to the HLA-DQ2/8 grooves (20). Recent studies 
have identified in the sequence motifs QXP the glutamine residues which are preferentially 
substrate of TG2-mediated deamidation. This represents an important tool for the 
prediction of toxic gliadin peptides (21). Although there are at least 50 T cell stimulatory 
epitopes in gluten proteins, a unique 33-mer peptide is the more immunogenic since it 
harbors six in part overlapping epitopes; moreover, it is resistant to the enzymatic 
degradation by gastric, pancreatic and brush border peptidase (22). It might reach in an 
intact and stimulatory form the immune districts of intestinal mucosa (22,23); furthermore, 
the 33-mer peptide does not require further processing in APC for T cell stimulation as it 
binds to DQ2 molecules with a pH profile that promotes extracellular binding (24).  
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The A-gliadin 33-mer have been reported to stimulate CD4+ T lymphocytes selectively 
isolated from small intestinal mucosa of CD patients (22,25,26,27). Importantly, T cell 
lines and clones from intestinal mucosa of CD patients recognize gliadin-derived peptides 
in the context of the disease-associated HLA-DQ2 and -DQ8 restriction molecules. By 
contrast, no evidence of T-mediated reactivity against dietary gliadin has been reported in 
normal, non-celiac mucosa (28,29). Moreover, it has been shown that gliadin-specific T 
lymphocytes from CD intestinal mucosa are mainly of Th1/Th0 phenotype and release, 
following gliadin recognition, prevalently pro-inflammatory cytokines, dominated by γ-
interferon (28,30,31). γ-Interferon-dependent signaling pathways have been found to be 
enhanced in CD. Signal transducer and activator of transcription 1 (STAT1) (32) and 
interferon regulating factor 1 (IRF1) have both been found more expressed in untreated CD 
and in treated CD mucosa in vitro challenged with gliadin (33).  
CD8+ T lymphocytes recognize peptides of 8–12 aminoacid length in the context of HLA 
Class-I molecules. Peptides interact with HLA-Class-I molecules through specific 
aminoacid and in determined positions known as binding motifs which vary depending on 
the type of HLA Class-I molecules (34). On the basis of the capacity of a panel of gliadin 
peptides to bind HLA-A2.1 molecules, we recently identified a peptide, mapping the 123–
132 position of A-gliadin (A-gliadin 123–132, pA2) which is selectively recognized by 
CD8+ T lymphocytes from HLA-A2.1-positive celiac patients (35). This peptide induced 
γ-interferon production and cytotoxic activity by peripheral blood mononuclear cells from 
treated CD patients.  
More recently, attention has been directed to the possible involvement of innate immune 
mechanisms in CD (36,37). 
In particular, Maiuri et al. (37) showed that the synthetic peptide α-gliadin 31–43 
(LGQQQPFPPQQPY) is able to upregulate the expressions of interleukin (IL)-15, of the 
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enzyme cyclooxygenase-2 (COX-2) and of the cell activation markers CD25 and CD83 on 
LP macrophages, monocytes, and dentritic cells, without stimulating CD4+ T-cells.  
Barone et al. investigated the early events of celiac disease and in particular the interaction 
between gliadin peptides and intestinal epithelial cells. They found that the gliadin toxic 
peptide (P31-43) delays endocytic vesicle maturation and consequently reduces epidermal 
growth factor receptor (EGFR) degradation and prolongs EGFR activation, which in turn 
results in increased cell proliferation and actin modifications in celiac crypt enterocytes 
and in various cells lines (38). P31-43 enters CaCo-2 cells and intestinal enterocytes, 
interacts with early endocytic vesicles (39,40), reduces their motility and delays their 
maturation to late endosomes (39). Taken together, this information points toward an effect 
of certain gliadin peptides, i.e., P31-43, on endocytic function and indicates epidermal 
growth factor (EGF) signalling as one of the major pathways in the celiac intestine. 
In the 2011 Barone et al. (41) showed that P31-43 induces at least two main effects by 
altering the trafficking of cell vesicular compartments. This leads to overexpression of the 
trans-presented IL-15/IL5R alpha complex, an activator of innate immunity, and, due to 
cooperation of IL-15 and EGFR, the proliferation of crypt enterocytes with consequent 
remodelling of the CD mucosa. 
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1.1 Alanine-scanning P31-43 
 
Alanine-scanning mutagenesis is a simple and widely used technique in the determination 
of the catalytic or functional role of protein residues. Alanine is the substitution residue of 
choice since it eliminates the side chain beyond the β carbon and yet does not alter the 
main-chain conformation (as can glycine or proline) nor does it impose extreme 
electrostatic or steric effects.  
In order to gain insight on the structural details that make  P31-43 able to activate innate 
immunity mechanisms,  in  this study we analyzed  and compared the structural and 
biological properties of P31-43 peptide with those of its Ala-scanning mutants(Figure 2). 
We focused on identification of the critical amino acid residues of P31-43 that have a toxic 
functions. 
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Figure 2. Alanine scanning mutants of P31-43 
 
The conformational behaviors of the peptides were defined by considering both 
chromatographic and NMR spectroscopic data.  
HPLC profiles of P31-43 and almost all its Ala-mutants show two partially resolved peaks 
(Figure 3). We assumed that this atypical behavior was most likely a consequence of 
isomerization of two conformers, which is the result of the slow cis-trans isomerization of 
one of the four proline residues occurring in the sequences. For different peptides, it has 
been demonstrated that two adjacent prolines may cause the presence of slow 
interconverting cis–trans isomers with respect to the amide bond in solution.(42,43). The 
partial rotational hindrance around the Pro–Pro bond may explain the slow mutual 
conformational interconversion that causes peak splitting during HPLC analysis. Mutation 
of each residue in the synthetic peptide resulted in a unique single peak (Figure 3).  Based 
on the chromatographic behaviors of the peptide analogues, it was deduced that the 
Xaa_Pro bond with exceptionally low rate of isomerization (ms) is contained in the trait 
FP8P9, and particularly involves P8.  
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Figure 3. HPLC profiles of P31-43 and three of its alanine scanning mutants  
 
NMR analyses in water confirmed the presence of multiple conformers with inter-
conversion rates from slow to fast. For P31-43, Ala6 and Ala7 analogues, spectral 
overlapping hindered to confidently identify all the components of the molecular 
ensembles.  
 
Ala6 
Ala7 
Ala8 
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Figure 4. NMR analyses of P31-43(A), Ala6(B), Ala7(C) 
 
However, the structure characterized by P6,P8,P9,P12 in trans configuration was probably 
the most represented in solution (Figure 5). 
 
C 
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Figure 5. Structure representation of P31-43 in solution 
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1.2 Effects of Ala-mutant on cell culture CaCo2 
 
 
EGFR signaling to the nuclei, to induce proliferation, is well characterized (44,45). Upon 
EGF linking to the EGFR, a signaling cascade starts, that involves sequential 
phosphorylation of downstream effectors such as ERK. The MAPK-ERK 1–2, like all 
mitogen-activated-kinases (MAPKs), is one of the essential signaling molecules that 
convert environmental inputs into influences on a plethora of cellular programs, including 
proliferation (46). Moreover, most of the MAPK, including ERK, are stress sensors that 
can be activated by different inputs (47). Only phosphorylated ERK can transduce to the 
nuclei, where it can start trans-activation of several genes that can induce cell proliferation 
and other biological effects (48,49).  
To date gliadin peptides and in particular P31-43 are able to enhance proliferation of celiac 
enterocytes in a EGFR/ERK dependent way and to delay the trafficking and degradation of 
EGFR at the epithelial level, suggesting a role of EGFR activation in CD, particularly in 
determining the crypts hyperplasia and the tissue remodelling of the CD intestine (38). 
Moreover P31-43 is also able to reduce TEER in CaCo2 layers. 
In this study we have tested the Ala-mutants of P31-43 to identification the critical amino 
acid residues of P31-43 that can induced tissue damage. 
We used cell culture CaCo2 and we evaluated ERK phosphorylation and TEER.  
Interesting, eleven of thirteen Ala mutant are able to increase ERK phosphorylation similar 
to P31-43, but two peptide, Ala6 and Ala7, not induced this increase (Figure 5). 
We tested Ala6 and Ala7 and one, Ala13, that have the same effect on ERK 
phosphorylation like P31-43, on a CaCo2 monolayer, to investigate their effects on 
intestinal integrity.  Interesting Ala 13 is able to reduce TEER of caco2 layers like to P31-
43, instead two Ala-mutant, Ala6 and Ala7 are similar to the untreated. 
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Figure 6. Western blot analysis revealed that P3143 increase phosphorylation of ERK 
compared two Ala-mutant, Ala6 and Ala7. 
 
 
 
Figure 7. P31-43 is able to reduce TEER of caco2 layers, instead two Ala-mutant, Ala6 and 
Ala7 are similar to the untreated 
 
NT 
P31-43 
Ala13 
Ala6 
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Conclusive remarks 
 
 
Gluten is a complex mixture of polypeptides. The main immunogenic peptides of gluten 
belong to a family of closely related proline and glutamine-rich proteins called prolamines 
(15% proline and 35% glutamine residues). CD is triggered by peptides that result from the 
fragmentation of prolamines, and are not digested by human proteases because the high 
proline and glutamine content prevents complete proteolysis by gastric and pancreatic 
enzymes, and long oligopeptides that are toxic to coeliac sprue patients build up in the small 
intestine.In vitro and in vivo studies have demonstrated that a 25-mer, P31-43,  peptide from 
gliadin is not digestible by gastric, pancreatic, and intestinal brush-border membrane 
endoproteases. This and other peptides have been identified as the principal contributors to 
gluten immunotoxicity.  
It has been demonstrated that P31-43 is able to increase ERK phosphorylation and to 
decrease TEER on CaCo2 cells. In the present study we performed Alanin-scanning of P31-
43 and tested its mutant on CaCo2 cells. 
We observed  that Ala mutant of P31-43, in particular, Ala 6 and Ala 7 peptides, not induced 
this toxic effects on CaCo2 cells. We also observed that the replacement of amino acid 
residues in position 6 and 7 induces a conformational change of the peptides, as showed by 
HPLC profiles. The absence of toxic activity of the latter may depend both on the 
conformational change or the specific amino acid residues. Further experiments are needed 
to test the harmless of these  two peptides using other biological  system as the system of 
organ culture. If confirmed these data could lead to search grains in which this amino acid 
changes are still present and they could be tested in celiac patient. 
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2. Autoimmunity in potential CD patient 
 
 
Gluten is able to induce the production of autoantibodies that can be found in the serum of 
CD patients and that have, from a diagnostic viewpoint, a very high sensitivity and 
specificity (50). These autoantibodies recognize an endomysial antigen known today as 
transglutaminase 2 (TG2) (51). It is also well known that in CD patients anti-TG2 
autoantibodies are produced at intestinal level (52), and can be deposited on the 
extracellular TG2 in the mucosa of small intestine (53), even before passing into 
circulation and being measurable in serum. These deposits are localized below the 
basement membrane, along the villous and crypt and around mucosal vessels (53). In our 
paediatric population, deposits of immunoglobulin (Ig)A anti-TG2 are present in 96% of 
coeliac patients with overt disease (54). Patients with serum positivity for anti-TG2 and 
normal duodenal mucosa, or with slight signs of inflammation, are defined today as 
potential coeliac patients (55). In this group of patients intestinal deposits of IgA anti-TG2 
are found less often (54,56). However, their presence is relevant, as it has been associated 
with the risk of developing frank villous atrophy (56). Several studies have reported that 
when specimens of duodenal mucosa are cultured for 24–48 h in medium alone and with 
peptic–tryptic digest of gliadin (PTG) (57,58)  or with peptide 31–43 (P31–43) (58,59) , 
there is a production of anti-endomysial antibodies in organ culture supernatants in CD 
patients, but not in controls. 
More recently, similar data have been obtained measuring IgA anti-TG2 antibodies in 
supernatants of cultured biopsies from CD patients untreated and on a gluten-free diet (60-
62). This test has been proposed for diagnostic purposes, particularly in patients with 
normal mucosa. However, in this regard the information on potential CD patients is poor 
and scanty. 
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The aim of our work was to investigate the presence of anti-TG2 intestinal antibodies in 
patients with potential CD, and identify the most suitable detection test for this purpose. 
We compared two assays: the search for intestinal deposits of IgA anti-TG2 and 
measurement of the same antibodies in the supernatants after organ culture of duodenal 
biopsies. We detected mucosal deposits of anti-TG2 antibodies in 68% of potential CD 
patients, confirming our previous findings (54) ; at the same time, we showed in the same 
patients that a higher number (96%) secreted these antibodies into culture supernatants. 
The titres of secreted anti-TG2 antibodies of potential CD patients were lower than those 
observed in active CD patients and correlated significantly with serum titres. It is likely 
that a correlation exists between intestinal antibody titres and severity of mucosal damage. 
In our hands, the assay showed a sensitivity and specificity of 97·5% and 92·3%, 
respectively, differing from the search of mucosal deposits that showed sensitivity and 
specificity of 77·5% and 80%, respectively, in the same population.  Our data also showed 
that gliadin peptides do not influence intestinal anti-TG2 antibody production in patients 
with active CD and, as expected, in control subjects.Moreover, the intensity of mucosal 
deposits seemed to increase in potential CD patients in response to culture with gliadin 
peptides, while in the majority of patients the titres of secreted autoantibodies did not show 
a substantial increase.We have demonstrated that to detect intestinal anti-TG2 antibodies, 
the sensitivity and specificity of the anti-TG2 supernatant are higher than those of mucosal 
deposits. This test could prove useful in clinical practice to predict evolution to mucosal 
atrophy in potential coeliac patients and to identify patients with gluten sensitivity who 
lack CD-associated serum autoantibodies. 
These data have been published as Article on Clinical Experimental Immunology, for 
the manuscript see below. 
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3. Immunoregulatory pathway in potential CD patient 
 
The characteristic features of CD histology have always been considered to be a villous 
atrophy, crypt cell hyperplasia, and increased number of intraepithelial lymphocytes (IELs) 
(63). However, more recently, it has become increasingly evident that CD is not restricted 
to severe gluten-dependent enteropathy. Since 1993, Ferguson et al. (64) proposed the 
expression of potential CD to indicate subjects with a normal, or almost normal jejunal 
mucosa, but with immunological abnormalities similar to those found in celiac patients 
(64). Recently, this condition has been redefined and related to people with a normal small 
intestinal mucosa who are at increased risk to developing CD, as indicated by positive CD 
serology (65). 
Although the pathogenesis of CD remains not fully unraveled, it is known that gluten 
peptides are deamidated by tissue transglutaminase and presented by HLA-DQ2+ or HLA-
DQ8+ antigen-presenting cells to lamina propria CD4+ T cells (65,66). Upon activation, 
the lamina propria CD4+ cells polarize along the T helper 1 (Th1)-type pathway, as 
substantiated by their ability to produce large amounts of interferon γ (IFNγ), the main 
cytokine of Th1 response (67,68). In untreated celiac mucosa, the production of IFNγ is 
massively increased and its secretion can be observed in organ cultures from CD patients 
on a gluten-free diet, and in lamina propria derived T-cell clones upon stimulation with 
gliadin peptides (68-70). However, beside the adaptive immunity, the innate immune 
response is necessary for the phenotypic expression and pathologic changes characteristic 
of CD (71). Interleukin-15 (IL-15), a potent pro-inflammatory cytokine upregulated in the 
intestinal epithelium of CD, is thought to have pleiotropic function at the interface between 
innate and adaptive immunity (72,73). 
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At the same time, an enhanced expression of anti-inflammatory cytokines, such as IL-10, 
has also been observed in CD. In fact, in untreated CD patients the levels of IL-10 are 
higher, but the ratio IL-10/IFNγ is significantly lower in comparison with inflamed non-
celiac, control, and treated CD mucosa (74,75). Interestingly, the number of CD4+CD25+ 
T regulatory cells that express the forkhead box P3 transcription factor (Foxp3+) 
(Foxp3+Tregs) is significantly increased in the small intestinal mucosa with active CD 
(76,77). Furthermore, our recent studies have revealed that in active CD Foxp3+Tregs are 
functionally active, but their suppressive capacity might be impaired by pro-inflammatory 
cytokines, such as IL-15 (77). 
Also potential CD shows markers of enhanced inflammatory reactions as shown by the 
high level of IFNγ mRNA and densities of tumor necrosis factor-α-positive cells in the 
lamina propria (78); at the same time, in this condition the number of FoxP3-expressing 
cells is higher (79). 
Evidence suggests that CD develops gradually from normal villous architecture with only 
an epithelial lymphocytosis, through partial to total villous atrophy. The innate and 
adaptive mucosal systems are tightly controlled by various regulatory circuits, and it is 
possible that defects in such mechanisms could have a role in this dynamic process of 
mucosal damage in CD. In this respect, we think that potential CD represents an early 
stage of disease, and accordingly a good condition to clarify the early immunological 
events implicated in the onset of CD. For this purpose, initially we investigated in 
duodenal biopsies from potential CD subjects the state of immunological activation, with 
analysis of cytokines involved in both innate and adaptive immune responses, such as IL-
15 and IFNγ. Thereafter, to clarify the role of immunoregulatory mechanisms, we 
evaluated the expression of anti-inflammatory cytokines and the number of Foxp3+Tregs. 
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Finally, we evaluated the functional capacity of intestinal Foxp3+Tregs, obtained from 
potential CD patients and the role of IL-15 on their suppressive function. 
We provide evidence that in potential CD, despite the absence of mucosal damage, there 
are clear signs of infl ammation; in particular, our data suggest that in duodenal mucosa of 
these patients, T cells seem to be activated and diff erentiating toward a Th 1 pattern. 
Indeed, IL-2 RNA expression is increased in the mucosa of potential CD when compared 
with controls and active celiacs, confirming our previous data (80). Also, IFN γ -RNA 
expression, as well as the percentage of IFN γ + CD4 + cells, is significantly increased. 
Interestingly, IFN γ levels correlate with IEL infiltration, in agreement with previous data 
showing that the majority of IFN γ is produced in the epithelium (75)  
Our data suggest that regulatory mechanisms have a crucial role to downregulate the 
inflammation in early phase of CD. We have shown that in this condition there are two 
factors that maintain the suppressive action of Foxp3 + Treg: they are the high IL-10 
expression and a low sensitivity to pro-inflammatory stimuli, such as IL-15. 
These data have been published as Article on The American Journal of Gastrenterology, 
for the manuscript see below. 
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4. Correlation between levels of anti-TG2 and mucosal damage degree 
 
Coeliac disease (CD) is characterized by highly specific autoantibodies directed against 
transglutaminase 2 (TG2) (51). It is now well known that serum levels of anti-TG2 
correlate with intestinal damage (81,82). This finding has been considered in the recently 
revised European Society for Paediatric Gastroenterology Hepatology and Nutrition 
(ESPGHAN) criteria, and used to avoid biopsies in symptomatic patients with high titres of 
anti-TG2 (83). CD-specific autoantibodies disappear from serum after the beginning of a 
gluten-free diet (GFD) (84). 
Anti-TG2 antibodies are found both in blood and small intestine, where they are produced, 
and have been shown to co-localize with extracellular TG2 in the active phase of the 
disease (53). In recent decades several techniques have been used to reveal intestinal 
production of anti-TG2 antibodies, such as measurement in faeces (85) or duodenal juice 
(86), or in supernatants of cultured biopsies (59,60,62), the detection of mucosal deposits 
(53) or of plasma cells secreting them (87) and their expression by phage display library of 
RNA coding (52). Some assays were considered unreliable as diagnostic tests (88); others, 
even if with high diagnostic sensitivity and specificity, too demanding to be performed 
routinely (52). 
We have demonstrated that the measurement of antibodies released into culture 
supernatants is more sensitive than detection of their deposits to assess intestinal 
production of anti-TG2 in patients with potential CD (89). Picarelli et al. have shown 
recently that the organ culture system is a useful tool to assist the histology in diagnosing 
CD, mainly in cases without villous atrophy or in seronegative patients (90). Concerning 
patients on a gluten-free diet (GFD), the same authors showed that anti-endomysium 
(EMA) was not found in supernatants of biopsy samples cultured with medium alone, but 
was detected when biopsy samples from the same patients were treated with gliadin 
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peptides (91). Furthermore, Maki et al. (92) showed that, in the organ culture system 
conducted with biopsies of treated CD patients, gliadin induced secretion of autoantibodies 
into culture supernatants, reduced epithelial cell height and increased the density of lamina 
propria CD25+ cells. However, these changes could be demonstrated only in biopsies from 
CD patients who had recently started a GFD, in when the small-intestinal mucosal TG2-
specific IgA autoantibody deposits were still present. 
 
It is well known that the disappearance of serum anti-TG2 is observed progressively after 
the beginning of a GFD. It has been considered a useful tool to evaluate the diet 
compliance, although it is not yet clear if it is helpful to assess complete histological 
recovery (93). 
The aims of our study were to correlate, in coeliac patients, the titres of intestinal 
antibodies and the degree of mucosal damage and to investigate the effect of GFD on their 
intestinal production.  
We showed that the intestinal production of these autoantibodies correlated with mucosal 
lesion degree only in active CD. Potential CD patients with Marsh 0 mucosa produced 
titres of intestinal anti-TG2 antibodies comparable to those with Marsh 1. Moreover, in this 
potential coeliac population intestinal anti-TG2 titres correlated with an increased number 
of CD25+ mononuclear cells in lamina propria, a proven marker of mucosa inflammation 
(94). 
Studies on the follow-up of CD patients on GFD (95) have shown that titres of circulating 
anti-TG2 antibodies decreased significantly during the first 12 months of the diet and then 
disappeared in the next 12 months. The disappearance of serum CD-specific autoantibodies 
was correlated with GFD compliance, but not always associated with the total recovery of 
small intestinal mucosa (93). Our data appear to show that the early disappearance of 
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circulating specific CD autoantibodies, following a strict GFD, does not mean the end of 
their intestinal production. After the disappearance from serum, anti-TG2 antibodies as 
deposits would disappear slowly from the intestine, and only after a long period of GFD, 
small intestinal mucosa would cease to produce them. 
Finally, our data show that in vitro 24-h PTG stimulation was not able to induce a 
statistically significant increase of antibody secretion in short-term GFD CD patients as 
well 
as in patients on long-term GFD. 
These data have been published as Article on Clinical Experimental Immunology , for the 
manuscript see below. 
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CHAPTER II 
“Food Allergy” 
1. Diagnosing and Treating Food Allergy 
 
Food allergy (FA) is a major health issue in western societies affecting between 5 and 10 % 
of young children (96). During the last decade in the United States pediatric FA diagnosis 
rates increased by 18%, however it has not been determined whether these findings are 
related to increased awareness and reporting. In any case, the use of specific medical 
diagnostic codes for FA does represent a real increase of the disease (97). It has been 
estimated that FA, in the United States alone, accounts for 30,000 emergency room visits 
and 150 deaths per year (98). In Italy, the number of hospital admissions due to food-
induced anaphylaxis doubled in the last 5 years (99). 
Food allergies can be broadly divided into IgE (type I hypersensitivity)- and non-IgE 
(usually type IV hypersensitivity)-mediated diseases; or mixed, involving other 
immunoglobulins, immune complexes and/or cell-mediated mechanisms. These differ in 
clinical presentation, diagnostic testing, and prognosis (100). IgE-mediated reactions are 
characterized by an acute onset of symptoms generally within 2 h after ingestion of or 
exposure to food. IgE-mediated reactions to food typically involve the skin, gastrointestinal 
tract, and respiratory tract and may include systemic reactions (anaphylactic shock). Non-
IgE-mediated immunological reactions (e.g., cell-mediated) include food–protein-induced 
enterocolitis, proctocolitis, and enteropathy syndromes. These conditions primarily affect 
infants or young children who present with abdominal complaints, such as vomiting, 
abdominal cramps, diarrhea, and occasionally blood in the stool and failure to thrive or poor 
weight gain. Examples of FA co-morbidities with mixed IgE- and non-IgE-mediated causes 
include eosinophilic gastrointestinal diseases and atopic dermatitis (101). 
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Oral food challenge still represents the gold standard for the diagnosis of FA in order to 
avoid unjustified diets. When the food considered for the challenge is still part of the 
patient’s diet, a strict elimination diet should be prescribed for at least 2 weeks before the 
OFC. The OFC is done by feeding gradually increasing amounts of the suspected food under 
observation by a physician over a period of hours, protracted for days when no immediate 
reaction occurs. 
Because the procedure carries a small risk of anaphylaxis, it should be conducted in a 
supervised medical setting where resuscitation equipment is available. The main problems of 
OFC are related to the wide variety of symptoms possibly related to immunological 
mechanism of FA that lead to difficulties in the interpretation of results and to the optimal 
timing and dosage of this procedure. A rather complex, double-blind placebo- controlled 
food challenge (DBPCFC), routinely used in research, is recommended in clinical settings 
only when patients report entirely subjective symptoms; whereas an open OFC without 
placebo is commonly used in children under the age of 3 years and when objective 
symptoms are present (102-104). Unfortunately, the diagnosis of FA is frequently 
incomplete, incorrect, or self-reported, and a correct diagnostic work-up, confirmed by OFC, 
seems to be adopted in only a minority of cases (105). 
Although numerous therapeutic treatment options are currently being investigated, dietary 
avoidance remains the primary treatment for FA (106). Inadequate nutritional status, growth, 
and dietary intakes have been demonstrated in children with FA (107). Altered growth status 
may be due to potential loss of nutrients caused by continued allergic inflammation and/or 
abnormal intestinal permeability caused by noncompliance with the diet, unbalanced diet 
and additional undiagnosed FA or inappropriate substitute foods (107). This highlights the 
need to make every effort to optimize nutrition because inadequate nutrient intake may 
worsen the risk of lower growth rates in this population. The elimination diet should be 
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considered carefully depending on: mechanism of FA; symptoms; nutritional status; and 
concomitant factors like food aversive behavior. A properly managed, well-balanced 
elimination diet prescribed with the help of certified dietitians, can lead to resolution of 
symptoms while maintaining or even optimizing nutritional status.  
Recent data strongly suggest that gut microbiota is important for oral tolerance development 
(108). Administration of the probiotic Lactobacillus rhamnosus GG (LGG) to food-allergic 
children (age\2 years, challenge-proven and affected by mild-to-moderate eczema) improved 
the eczema score significantly (108). Studies in infants with eczema who received formulas 
supplemented with LGG showed benefits in decreasing gastrointestinal symptoms (109). For 
instance, after a challenge study in infants allergic to cow’s milk proteins, fecal IgA levels 
were detected to be higher, and TNF-a levels were lower in the LGG applied group 
compared to the placebo (108). Nermes et al. (110) showed a significant decrease in IgA- 
and IgM-secreting cells in infants with atopic dermatitis treated with extensively hydrolyzed 
casein formula (eHCF) supplemented with LGG, suggesting that this particular probiotic is 
able to enhance gut barrier function and accelerate immunological maturation in infants with 
FA.  
Correct diagnosis of FA is crucial to ensure appropriate patient care. The essential criterion 
is a clear response to elimination diet, and other diagnostic tests are secondary to this. OFC 
plays a crucial role in the diagnostic approach to a child with suspected FA, but it is largely 
underutilized. 
Potential responsible factors contributing to the lack of a correct diagnostic work-up in the 
vast majority of cases could be numerous, and include lack of training on the procedure, 
increased reliability on screening methods, extensive time needed, fear of risk, and 
suboptimal fee reimbursement. A comprehensive nutrition assessment with appropriate 
intervention is warranted in all children with FAs to meet nutrient needs and optimize 
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growth. Frequently an elimination diet is absolutely necessary to prevent potentially life-
threatening food allergic reactions. 
These data have been published as Article on Current Pediatric Opinion , for the manuscript 
see below. 
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2. Potential beneficial effects of butyrate against food allergy 
 
Food allergy rates in children have rapidly increased with significant direct medical costs for 
the health care system and even larger costs for families with a food-allergic child. during 
the last decade, we observed a changing pattern in CMA with an increased prevalence, 
severity of clinical manifestations and risk of persistence until later ages in Western 
countries (111). Over the last twenty years rates of potentially life threatening reactions to 
food (anaphylaxis) have steadily risen in the developed world (99). For all these reasons, 
there is a strong need to develop effective strategies to stimulate oral tolerance acquisition 
and maintenance. The possible causes of food allergy become the target of intense scrutiny 
in recent years(112). Increasing evidence underline the importance of gut microbiome in the 
development of allergic diseases. It has been demonstrated that in early life the gut 
microbiome influence immune development, balance of Treg cells and bacterial metabolites 
which may increase the risk of food allergy. The colonizing bacteria originate mainly from 
the mother‘s gut and vaginal tract (113). After delivery, breast feeding continues to enhance 
the original inoculum by the introduction of specific lactic acid bacteria, Bifidobacteria and 
other bacteria from the mother‘s skin. These bacteria set the basis for intestinal microflora 
development and modulation. An imbalance in the compositional configuration of the gut 
microbiota, dysbiosis, alters the host-microbiota homeostasis, which is a requisite for the 
development and function of immune cells in the gut associated lymphoid tissue. The 
importance of this reciprocal regulation of the microbiota and immune system culminates in 
early infancy, when the balance between homeostasis and inflammation programs later 
disease risk. In particular, early exposure to commensal bacteria plays a crucial role in 
Th1/Th2 polarization and proper immune regulatory mechanisms. Regulatory T cells 
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(Tregs), that express the transcription factor Foxp3, are also critical for the induction and the 
maintenance of food oral tolerance and for the regulation of intestinal inflammation.  
Short chain fatty acids (SCFAs) such as propionate, acetate and butyrate are gut microbiota 
derived bacterial fermentation products that selectively expand Tregs in the large intestine 
(114). These SCFAs stimulate the expansion and immune suppressive properties of Tregs, 
such as the production of IL-10 (115). Among the SCFAs, butyrate has received particular 
attention for its multiple beneficial effects from the intestinal tracts to the peripheral tissues. 
The mechanisms of action of butyrate are multiple and involve also an epigenetic regulation 
of gene expression through the inhibition of histone deacetylase. In particular, the inhibition 
of histone deacetylase 9 and 6 increases Foxp3 gene expression, as well as the production 
and suppressive function of Tregs(116). The identification of bacterial metabolites, that 
affect host immunity, may be an interesting strategy to prevent and/or to treat food allergy 
and promote human health. 
These data have been published as Article on the book Butyrate: Food Sources, Functions 
and Health Benefits , for the manuscript see below. 
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2. An animal model to explore the mechanism of action elicited by 
Extensivly Hydrolized Casein Formula on cow’s milk allergy 
 
During the last decade, we observed a changing pattern in CMA with an increased 
prevalence, severity of clinical manifestations and risk of persistence until later ages in 
Western countries (111). In Italy, CMA is responsible for 42% of food-induced anaphylaxis 
in the pediatric population (99). For all these reasons, there is a strong need to develop 
effective strategies to stimulate oral tolerance acquisition and maintenance. 
Extensively hydrolyzed casein formula (EHCF) has been proposed for prevention and 
treatment of CMA. For infants with CMA, we have previously demonstrated that eHCF 
induces a faster oral tolerance acquisition if compared with other dietetic choices 
(hydrolyzed rice formula, soy formula and amino acid based formula) and that this effect is 
up-regulated by the addition of the probiotic Lactobacillus rhamnosus GG (LGG, 
Nutramigen LGG) (117-118). The exact mechanism of these effects are still largely 
unknown. Preliminary evidences suggested a possible immunoregulatory role elicited by 
small peptides derived from bovine casein (119-120).  
I aimed to investigate the mechanisms elicited by Extensivly Hydrolized Casein Formula 
(EHCF) and EHCF plus LGG in stimulating oral tolerance. To do this we used a well-
established animal model of CMA using a major antigenic peptide from bovine milk, beta-
lactoglobulin (BLG) (121). Two consecutive research phases were performed to explore the 
mechanism of action elicited by EHCF and EHCF plus LGG on CMA prevention and 
treatment. 
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3.1 Animal model in food allergy    
 
Animals models are being used to understand of IgE-mediated disease and to determine the 
allergenicity of novel proteins. Several animal models have provided important information 
for understanding some of the mechanisms of allergenicity. Examples of animal models 
include the mouse, rat, guinea pig, and dog. As in humans, animal models have an innate 
tendency to develop tolerance to the myriad of proteins ingested, and it is difficult to 
generate valid food allergy models. A number of methods have been introduced to bypass 
the state of tolerance and initiate a food hypersensitivity that reflects human IgE-mediated 
food allergy. 
The degree of sensitization should take into consideration the concentration of the allergen 
(high doses are known to induce tolerance); the allergen should be taken in context with the 
food source; the route (feeding and/or gavage are the recommended avenues) and duration 
of allergen exposure. And the age of the animal. 
Other considerations include the genetic predisposition (high and low IgE responders), the 
use of adjuvants and the isotype specificity response. In addition the allergenicity profile 
should be comparable to what exists in the human response to different allergens, for 
example, anaphylactic episodes induced by peanut allergens to oral/pharyngeal symptoms 
elicited by fruit and vegetable allergens in the oral allergy syndrome. The simple production 
of IgE and binding of IgE to relevant proteins should be considered insufficient without 
evidence of histamine release using in vitro tests to support cross linking of IgE to bound 
mast cells and basophils.The mouse model is the most representative in literature. Inbred 
strains of mice have been characterized as being either high or low IgE-responder animals 
for both inhalant and food allergens. 
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As in humans, two separate events are required: the first event is a sensitization phase and, 
in the case of mice, the production of two anaphylactic antibodies, IgE and IgG1; the second 
phase is characterized as the allergic challenge following re-exposure to the allergen at the 
site of the response. In both inhalant and ingestant sensitizations, short-term daily exposures 
over a period of days or long-term exposure once a week over several weeks have been 
shown to induce allergen-specific IgE/IgG1. Differences in strain MHCs have been 
suggested as a likely reason for differences in mouse models' responses to different 
allergens, which may parallel a genetic predisposition in humans. 
Cow's milk allergy (CMA) is a major cause of a transient food hypersensitivity in children. 
It involves the skin, respiratory tract, and gastrointestinal tract and can lead to systemic 
anaphylactic shock. In a study by Li et al. (122),6 several strategies were used to overcome 
oral tolerance in a mouse model and induce IgE-mediated cow's milk hypersensitivity. 
Three-week-old C3H/HeJ female mice were sensitized intragastrically with cow's milk plus 
cholera toxin as an adjuvant and were boosted five times at weekly intervals. Six weeks after 
the initial sensitization dose, mice were fasted and intragastrically challenged with two doses 
of CM 30 minutes apart. Hypersensitivity responses were assessed based on symptom 
scores, vascular leakage, plasma histamine release, PCA, serum antibody titers, skin testing, 
and histological examination. Symptom scores were identified by independent observation 
of the physical features. 
The model exhibited characteristics of IgE-mediated cow's milk-induced food allergy. 
Elevated allergen-specific IgE levels were shown to be associated with systemic 
anaphylaxis, whereas levels of IgG1 were not; PCA reactions induced by serum from 
sensitized mice were eliminated by heating; and significant plasma histamine from mast cell 
degranulation was in evidence, all of which are important features of IgE-mediated food 
allergy. Serum casein levels after oral challenge were consistent with intestinal permeability 
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studies and histologic examination revealed changes in both the GI and respiratory systems. 
The model was regarded to be useful for evaluating mucosal and systemic 
immunopathogenic mechanisms involved in IgE-mediated cow's milk allergy. 
Mice could prove valuable with respect to strain and allergen specificity in which related 
reactions may provoke information on the genetic basis of food allergen sensitization.  
 
 
3.2 Extensivly Hydrolized Casein Formula (EHCF) and  
EHCF plus LGG in stimulating oral tolerance 
 
The bioactive peptides generally contain 3–20 amino acids. The C- or N-terminal fragments 
are crucial for their activities. Activities are shown on the digestive system, the immune 
system, the cardiovascular system, the nervous system and body defense. Many of the 
bioactive peptides are derived from milk proteins. Examples are β-casomorphin (opiate 
activity), casein macro peptide (stimulation of release of CCK), β-casein fragments 
(angiotensin-I-converting enzyme inhibition), casein phosphopeptides (enhancement of 
mineral absorption), α-lactalbumin fragments (immune stimulation) and a wide range of 
antimicrobial peptides derived from caseins and whey proteins (123). Recently was report 
the identification of a peptide from yoghurts with promising potential for intestinal health: 
the sequence (94-123) of bovine β-casein. This peptide, composed of 30 amino acid 
residues, maintains intestinal homoeostasis through production of the secreted mucin MUC2 
and of the transmembrane-associated mucin MUC4 (124).  
Intestinal goblet cells are highly polarized secretory cells that reside throughout the length of 
the small and large intestine. They are responsible for production of the protective mucus 
coat by releasing the secreted mucin MUC2, a high-molecular-weight glycoprotein that is 
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stored within granules in their apical compartment. Mucus lubricates the intestinal surface, 
limits passage of luminal molecules into the mucosa, functions as a dynamic defensive 
barrier against enteric pathogens and acts as a substrate and a niche which the commensal 
flora can colonize (125). 
Probiotic bacteria are proposed to benefit human health mainly by our general mechanisms 
of action. First of all, probiotics can clearly exclude or inhibit pathogens, either through 
direct action or through influence on the commensal microbiota (126). Certain probiotic 
strains have the capacity of to enhance the epithelial barrier function by modulating 
signaling pathways, such as nuclear factor-B (NF-kB), Akt and mitogen- activated protein 
kinase (MAPK)- dependent pathways, which lead to for example the induction of 
mucus(127), or increased tight junction functioning (128). Moreover, most probiotic strains 
can also modulate host immune responses, exerting strain-specific local and systemic 
effects(129). Many of the interactions between probiotic bacteria and intestinal epithelial 
and immune cells are thought to be mediated by molecular structures, known as microbe- 
associated molecular patterns (MAMPs), which can be recognized through specific pattern 
recognition receptors (PRRs) such as Toll-like receptors (TLRs) (130) 
Lactobacillus GG is known to modulate immune functions via various pathways, including 
those involving enterocytes, monocytes, mast-cells, dendritic cells, and regulatory T cells. 
Lactobacillus GG may alters the generation of cytokines involved in IgE-mediated CMA, 
and thereby can positively modulate the major pathways involved in CMA 
pathogenesis(131).  
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3.3 CMA Prevention 
 
 
The design of the experiments is reported in Figure 8. Briefly, two weeks prior to 
sensitization period, mice were given three different experimental diets: control solid “milk-
free” pellet diet (Harlan Laboratories, Udine, Italy); EHCF (Nutramigen, Mead Johnson 
Nutrition, Evansville, IN, USA); or EHCF+LGG (Nutramigen LGG 1, Mead Johnson 
Nutrition, Evansville, IN, USA). The composition of the three experimental diets is 
presented in Table 1. After 14 days, mice were sensitized orally using a blunt needle on day 
0, 7, 14, 21, 28 with 20 mg of beta-lactoglobulin (BLG) (Sigma-Aldrich, Steinheim, 
Germany) homogenized in PBS (0.2 ml) mixed with 10 µg cholera toxin (CT) as adjuvant. 
One week after the last sensitization (day 28), acute allergic skin response was assessed and 
after 24 h, mice were challenged by gavage with BLG to determine anaphylaxis score and 
rectal temperature. On next day mice were sacrificed, blood samples were collected, and 
spleens were aseptically excised, lysed and cryopreserved. 
 
 
 
 
 
 
 
 
 
Figure 8 . To explore the effects of EHCF and EHCF plus LGG in CMA prevention 
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BLG-sensitized mice showed a significant higher acute allergic skin response and 
anaphylactic symptom score, as compared to control animals. All these effects were 
significantly reduced by pre-treatment with EHCF or with EHCF+ LGG, but the presence of 
LGG induced a more pronounced effect on acute allergic response (Figure 9). Similarly, 
BLG sensitized animals showed a significant increase in anti-BLG IgE serum level, IL-4 
production by spleen lysates, and intestinal permeability, compared to control animals. 
These effects were significantly inhibited by EHCF. The presence of LGG induced a more 
pronounced effect on all these variables (Figure 9). 
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Figure 9 . EHCF and EHCF plus LGG prevent the allergic response to the cow’s milk 
protein β-lactoglobulin (BLG) in a murine model of food allergy (A) acute allergic ear 
swelling response (B) anaphylactic symptom scores  (C) BLG-specific IgE (D) IL-4 from 
spleen lysates (E) intestinal permeability to plasma DX-4000 FITC. (B), independent 
samples t-test; (A-C-D-E): Mann-Whitney U Test; *p<0.01; **p<0.05. 
 
 
3.4 CMA treatment 
 
The design of the experiments is reported in Figure 10. Briefly, mice were sensitized orally, 
using a blunt needle on day 0, 7, 14, 21, 28 to 20 mg of BLG homogenized in PBS (0.2 ml) 
mixed with 10 µg CT as  adjuvant. After last sensitization mice were given three different 
experimental diet: control solid “milk-free” pellet diet; EHCF; or EHCF+LGG. The weight 
of the mice was monitored weekly. At the end of the 4-week treatment with different diets, 
acute allergic skin response was assessed and after 24 h mice were challenged by gavage 
with BLG to determine anaphylaxis score and rectal temperature. On next day mice were 
sacrificed, blood samples were collected, and spleens were aseptically excised, lysed and 
cryopreserved.  
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Figure 10 . To explore the effects of EHCF and EHCF plus LGG in the treatment of CMA 
 
 
Treatment with EHCF was able to significantly reduce acute allergic skin response and 
anaphylactic symptom score as compared to control animals. The presence of LGG induced 
a more pronounced effect on acute allergic response (Figure 11). Dietary treatment with 
EHCF induced a significantly reduction of anti-BLG IgE serum level, IL-4 production by 
spleen lysates and intestinal permeability increase (Figure11). 
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Figure 11 . EHCF and EHCF plus LGG reduce the allergic response to the cow’s milk 
protein β-lactoglobulin (BLG) in a murine model of food allergy (A) acute allergic ear 
swelling response (B) anaphylactic symptom scores  (C) BLG-specific IgE  (D) IL-4 from 
spleen lysates (E) intestinal permeability to plasma DX-4000 FITC. (B), independent 
samples t-test; (A-C-D-E): Mann-Whitney U Test; *p<0.01; **p<0.05 
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Conclusive remarks 
 
 
We obtained an effective oral BLG sensitization in C3H/HeOuJ mice characterized a skin 
reaction, occurrence of severe allergy-related symptoms, body temperature reduction, 
associated with an increased IL-4 and anti-BLG specific IgE production. These results 
resembled what previously obtained by others. (132-133). In addition, a significant increase 
in intestinal permeability was demonstrated. An increase of gut permeability is a common 
feature in patient affect by food allergy (Kirsi M. Järvinen, M 2014). Intestinal permeability 
has been considered a crucial factor in the oral tolerance mechanism.  These features were 
used in our study as biomarkers to explore the effects of a dietary intervention with EHCF 
alone or in combination with LGG. 
Our results show that EHCF, at least in part through a modulation of  IL-4 and anti-BLG 
specific IgE production, is able to prevent oral BLG sensitization. As demonstrated by a 
significant decrease in acute allergic skin response, anaphylactic symptoms, and body 
temperature and intestinal permeability modification. These findings are in line with those 
previously reported in clinical studies demonstrating an allergy preventive effect elicited by 
extensively hydrolysed casein formulae (134-135). EHCF has been proposed as appropriate 
alternative to breast milk for allergy prevention in infants at risk. (136-139). 
Similar effects were obtained in mice treated with EHCF after sensitization with BLG. In 
those mice we observed a decrease in IL-4 and anti-BLG specific IgE that lead a reduction 
in anaphylactic reactions and restoring of intestinal permeability. These findings support the 
EHCF efficacy previously demonstrated in clinical studies that considered this formulae the 
first choice to treat patients affect by CMA (140-142). These result was reinforced with 
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demonstrated that EHCF induces a faster oral tolerance acquisition if compared with other 
dietary intervention. (118). 
All these date provide evidences on a immunoregulatory effect elicited by EHCF that could 
be due to the presence of immunoregulatory peptides derived from casein hydrolysis. Both 
suppressive and enhancing effects on immune variables have been found in studies 
investigating casein-derived peptides (120). These date suggest that the oral ingestion of the 
casein phosphopeptide preparation may reduce allergic symptoms in animals through 
suppression of absorption of allergens from the intestinal tract, suppression of IgE formation 
specific to allergens and/or inhibition of binding of allergens to their IgE on mast cells. One 
of the best characterized immunomodulatory peptide derived from bovine milk caseins is 
casein phosphopeptide from β-CN (f1-28) that has been show a mitogenic activity on mouse 
spleen and rabbit Peyer’s patch cells and stimulated their IgA production(143). Moreover, it 
was able to reduced allergic symptoms mediated by IgE in NC/Jic Jcl mice treated with 
ovalbumin. The author have also demonstrated that the spleen cells of mice given a peptide-
added diet produced lower IL-4 than those of control diet (144).  
Recently a β-CN (f 184–202) peptide has been shown to be NFκB inhibitory peptide(123) 
while the peptide (94-123) of bovine β-casein from yoghurt has been reported to maintain 
intestinal homoeostasis through production of the secreted mucin MUC2 and of the 
transmembrane-associated mucin MUC4.(124). Mucus lubricates the intestinal surface, 
limits passage of luminal molecules into the mucosa, functions as a dynamic defensive 
barrier against enteric pathogens and acts as a substrate and a niche which the commensal 
flora can colonize (125) and it could be another of the putative mechanism of the positive 
effects of EHCF as demonstrated by our result of a protective effect on intestinal 
permeability. 
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In the two experimental phases of this study the effect of EHCF was reinforced by the 
addition of the probiotic Lactobacillus rhamnosus GG. This date further supported clinical 
evidences showing a more potent activity elicited by EHCF LGG on CMA-related 
symptoms and gut inflammation [28], and on oral tolerance acquisition which resulted in a 
higher rate of acquisition of tolerance after 12 months of treatment[7,8]. Probiotics have 
been reported to modulate immune response and their supplementation has been proposed as 
a preventive intervention (145). LGG is known to modulate immune functions via various 
pathways, including those involving enterocytes, monocytes, mast-cells, dendritic cells, and 
regulatory T cells (146). In particular LGG has been able to suppress Th2 responses such as 
reduced hypersensitivity scores and lowered serum CMP-specific IgG1 and promote Th1 
responses by causing elevated IFN-γ and CMP-specific IgG2a levels in mice that were 
sensitized with the whole CMP (147). In cell culture of CaCo2 has been demonstrated that 
LGG is also able to suppress TNF-α-induced NF-κB activation as evidenced by maintenance 
of epithelial barrier integrity against pro-inflammatory cytokine stimuli and by a reduction in 
the secretion of specific chemokines induced by activation of this signal transduction 
pathway (148). Finally, it has been recently demonstrated that daily supplements of LGG 
resulted in a dramatic shift in the composition of the intestinal microbial community with a 
large increase in the number of taxa previously associated with a decreased risk for the 
development of allergy and atopy (149) and taxa with the potential to produce butyrate 
(150).  
We cannot exclude that even components included in the formulae used in the study could 
lead contributed to immune effects evidences in both experimental phases. Among this the 
polyunsaturated fatty acids (PUFA) that has been demonstrated are able to reduce the 
incidence of food allergy and IgE-associated eczema in children at risk for atopy (151). 
Moreover, dietary supplementation with PUFA largely reduce ovalbumin allergy in mice 
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(152) and prevent oral sensitization to the cow’s milk protein through  the induction of 
functional Treg (153) 
In conclusion the result of this study demonstrated an immunoregulatory activity elicited by 
EHCF that is able to efficiently contour act several mechanisms involving in CMA 
pathologies. According to previous clinical trials the presence of LGG is able to up-regulate 
the magnitude of these effects. 
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Technologies 
 
HPLC Analysis 
HPLC of the synthetic peptide was performed using a reverse-phase column (2.0 mm i.d. × 
250 mm, C18, 5 μm; Phenomenex, Hesperia, CA) with a flow rate of 0.2 mL/min on an 
Agilent 1100 modular system with an integrated diode array detector (Palo Alto, CA). 
Solvent A was 0.1% trifluoroacetic acid (TFA) (v/v) in water; solvent B was 0.1% TFA in 
acetonitrile. A 60 min gradient of 5–60% buffer B was used. The chromatographic 
separation of the peptide was performed at ambient (25 °C), low (∼4 °C), and high (50 °C) 
temperatures, using a thermostatic column holder or chilling the column in an ice-cold bath. 
 
Cell culture and treatments  
Caco-2 cells were cultivated in Dulbecco Modified Eagle’s Medium DMEM, (GIBCO) 10% 
FCS (GIBCO), 100 units/ml penicillin-streptomycin (GIBCO), 1 mM glutamine. LPS-free 
P31-43 and its synthetic mutants (Inbios, .95% purity, MALDI-toff analysis as expected) 
were obtained by Ultrasart-D20 (Sartorius AG, Goettingen, Germany) filtration. LPS levels 
were below detection (,0.20 EU/mg), assessed by commercial QCL-1000 kit (Cambrex 
Corporation, New Jersey USA). P31–43 sequence: LGQQQPFPPQQPY and its ala mutants 
were used at 500 mg/ml and the caco2 cells were stimulated for 30min. 
  
Immunoprecipitation and immunoblotting 
Cell lysates were prepared as described previously(154) and the phosphorylated form of Erk 
 [p-Erk] was detected using anti-p-Erk E-4 mouse monoclonal antibody (Clone E4 Santa 
Cruz). Total Erk was detected using Erk rabbit polyclonal antibody anti-Erk K23 (clone 
K23, Santa.Cruz).  
Briefly, 2 micrograms of anti p-Erk E-4 immunoprecipitating mouse monoclonal antibody 
(clone 528,Santa Cruz) were added to 1 milligram of cell lysates in 500 micro litres of lysis 
buffer kept for 2 h at 4°C with gently rocking. Thirty micro litres of 1:1 protein-A agarose 
(Pierce) was added and the mixture was rocked gently for 1 h at 4°C, before centrifugation 
at 12 000 g for 5 min at 4°C. The immunoprecipitate was washed three times with 500 ml of 
lysis buffer. Proteins were separated by SDS-PAGE and immunoblotted with anti-
phosphotyrosine (p-Tyr) mouse monoclonal antibody (clone 4G10 from UBI) or anti-EGFR 
rabbit polyclonal antibody (clone 1005, Santa Cruz). Electrophoresis and immunoblotting 
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were all performed as described elsewhere (154). Densitometric analysis was performed as 
follows. Band intensity was evaluated by integrating all the pixels of the band without the 
background, calculated as the average of the pixels surrounding the band. Phosphorylation 
increments (Pi) were calculated from the ratio of phosphorylated (P) and unphosphorylated 
(UP) bands in treated (t) and untreated cells (ut) as follows: Pi=(Pt/UPt)/(Put/UPut). 
 
Data bank analysis 
Swissprot, Trembl and InterPro data banks were searched for sequences matching peptide 
P31–43, by using Blast and FastA. Sequence alignment was performed by using ClustalW 
and visualised by PrettyPlot from the EMBOSS suite. 
 
Statistical analysis 
Statistical analysis was performed where appropriate by employing Student’s t-Test; 
asterisks mark results whereP,0.05. 
 
 
Acute allergic skin response, anaphylaxis symptom score and body temperature 
Acute allergic skin response was evaluated by ear thickness measurement determined in 
duplicate using a digital micrometer (Mitutoyo, Lainate, Milano) 1 hour after intradermal 
injection of 0.5μg of BLG in the ear pinnae. The ear swelling was calculated by correcting 
the allergen-induced ear thickness with the basal ear thickness. The delta ear swelling was 
expressed as μm. 
Within one hour following the oral BLG challenge (50 mg in PBS by gavage), anaphylaxis 
was assessed by measuring changes in body temperature and recording symptoms score. 
Rectal temperature was measured before and 60 min after oral challenge. Hypersensitivity 
symptoms were scored by an investigator blind to the study group assignment, as previously 
described (121): 0 = no symptom; 1 = scratching and rubbing around the nose and head; 2 = 
reduced activity; 3 = activity after prodding and puffiness around the eyes and mouth; 4 = no 
activity after prodding, labored respiration, and cyanosis around the mouth and the tail; and 
5 = death. 
 
Serum BLG-specific IgE 
Blood samples obtained by intracardiac puncture from mice were collected into serum 
separator tubes. The serum portion was separated by centrifugation at 10,000 x g for 5 min 
91 
 
at 20 ºC. Serum samples were then aliquoted into Eppendorf tubes and stored at -20 ºC until 
being analyzed. BLG-specific serum IgE were detected by ELISA. Briefly, 96-well plates 
were coated with 100 μg/mL of BLG in 0.1 mol/L Na-bicarbonate/carbonate coating buffer 
(pH 9.6). After overnight incubation at 4 °C, plates were washed 3 times with 150 μl of PBS 
plus 0.05% Tween-20 (PBS-T) and blocked with 100 μl of 2% BSA in PBS-T for 2 h at 37 
°C. Subsequently, the plates were washed 3 times and 100 μl of serially undiluted serum 
samples were added to the wells and incubated at 37 °C for 90 min. Plates were then washed 
3 times, and 100 μL of horseradish peroxidase (HRP) conjugated anti-mouse antibodies 
were added to each well. The plates were again incubated at 37°C for another 60 min and 
washed 3 times. Then, 100 μl of TBS were added to each well and 15 min were allowed for 
the development of colorimetric reactions. Absorbance were read at a wavelength of 450 nm 
in a microplate reader.  
 
Interleukin 4 in spleen lysates 
Spleen lysates were obtained as previously described (155). Briefly, individual spleens were 
placed in Eppendorf tubes containing 0.5 ml of lysate buffer. The spleen cells were lysed 
and homogenized by sonication for 30 s on ice. Supernatants were collected after 
centrifugation at 17,500 g for 10 min at 4 ºC and stored at -20ºC. Interleukin-4 (IL-4) from 
spleen lysates were analyzed by commercially available ELISA kits following the 
manufacturer’s protocol.  
 
Intestinal permeability in vivo 
From each study group of the two experimental phases (prevention and treatment) three 
animals were used to investigate intestinal permeability, as previously described (156). 
Briefly, mice were fasted for 6 h and then gavaged with 4,000 Da FITC-labeled dextran 
diluted in water (TdB Consultancy AB, Uppsala, Sweden) (500 mg/kg, 125 mg/ml). After 2 
h, blood (500 μl) was collected from intracardiac puncture and centrifuged (3,000 rpm for 15 
min at RT), and FITC-dextran concentration in plasma was determined by 
spectrophotometry (excitation wavelength 485 nm; emission wavelength 535 nm; HTS-7000 
Plus-plate-reader; Perkin Elmer, Wellesley, Massachusetts, USA),  
 
Statistical analysis 
For categorical variables, the χ2 test and Fisher’s exact test were used. Results were reported 
as means and 95% confidence interval (CI) and as median and interquartile range 
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(minimum-maximum) due to non-parametric distribution (established by the Kolmogorov 
test). The level of significance for all statistical tests was 2-sided, p<0.05. SPSS 16.0 for 
Windows software (SPSS Inc, Chicago, Ill., USA) was used for data analyses. 
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